Pharmacogenomic technologies: a necessary "luxury" for better global public health?
Globalization and Health, January 2011
Catherine Olivier, Bryn Williams-Jones
Pharmacogenomic technologies aim to redirect drug development to increase safety and efficacy of individual care. There is much hope that their implementation in the drug development process will help respond to population health needs, particularly in developing countries. However, there is also fear that novel pharmacogenomic drugs will remain too costly, be designed for the needs of the wealthy nations, and so constitute an unnecessary "luxury" for most populations. In this paper, we analyse the promise that pharmacogenomic technologies hold for improving global public health and identify strategies and challenges associated with their implementation.
|Readers by professional status||Count||As %|
|Student > Bachelor||13||16%|
|Student > Master||12||15%|
|Student > Ph. D. Student||9||11%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||18||22%|
|Nursing and Health Professions||6||7%|
|Agricultural and Biological Sciences||4||5%|